Browse the evidence

Multi-receptor incretin drugs are associated with an increased risk of adverse events (primarily gastrointestinal) compared to placebo, but do not significantly increase the risk of serious adverse events.

Be aware that multi-receptor incretin drugs commonly cause gastrointestinal side effects like nausea, which may lead to discontinuation for some. However, the risk of serious health events is not significantly higher than placebo. Discuss potential side effects with your doctor and report any severe or persistent symptoms.

Short-term selective dietary fat restriction (30% calorie reduction) decreases dopamine D2/3 receptor binding potential and neural activity in brain reward regions, leading to increased selection of high-fat, high-carbohydrate foods.

If you are on a low-fat diet, you may find yourself craving high-fat, high-carb foods more intensely. This is likely due to changes in your brain's dopamine system, not just hunger. Be aware that this biological shift can make sticking to a low-fat diet harder, even if you feel satiated by the food itself.

For polygenic obesity, precision medicine approaches targeting specific genetic variants or phenotypes have not yet translated into reliable clinical guidance for selecting obesity medications, making early weight loss response the only consistent predictor of long-term efficacy.

Do not rely on genetic testing or complex phenotyping to choose your obesity medication right now, as it does not reliably predict success for common obesity. Instead, use a 'trial and error' approach guided by side effect profiles, comorbidities, and patient preference. The most important indicator of whether a medication will work for you long-term is whether you lose at least 5% of your body weight within the first 12-16 weeks.

Epicardial adipose tissue (EAT) contributes to Heart Failure with Preserved Ejection Fraction (HFpEF) through two distinct mechanisms: mechanical pericardial restraint and local inflammatory/fibrotic secretion.

For patients with HFpEF, managing epicardial fat is crucial. While general weight loss helps, specific interventions like bariatric surgery or Mediterranean-style diets have been shown to reduce EAT volume and improve heart mechanics. Monitoring EAT via imaging can help assess risk and treatment efficacy.

Visceral fat accumulation activates the Renin-Angiotensin-Aldosterone System (RAAS) and Sympathetic Nervous System (SNS), leading to hypertension and sodium retention, independent of dietary salt intake.

High blood pressure in obesity is driven by hormones from belly fat, not just salt. Reducing visceral fat helps normalize these hormones and lower blood pressure.

Obesity increases the risk of various cancers, including breast, endometrial, ovarian, kidney, thyroid, and gastrointestinal cancers, through mechanisms involving chronic inflammation, adipokine secretion, and epigenetic dysregulation.

Obesity increases your risk of several types of cancer, including breast, endometrial, and gastrointestinal cancers. This risk is driven by chronic inflammation and hormones secreted by fat tissue.

Roux-en-Y Gastric Bypass (RYGB) and Laparoscopic Sleeve Gastrectomy (LSG) induce significantly greater cardiac reverse remodelling (reduction in left ventricular mass and concentric remodelling) than Laparoscopic Adjustable Gastric Band (LAGB) in obese patients.

If you are considering bariatric surgery for obesity, the type of surgery matters for your heart health. Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (LSG) are superior to Gastric Banding (LAGB) in reversing the structural changes in the heart caused by obesity. This benefit is driven by the greater reduction in visceral and epicardial fat, not just total weight loss. Discuss cardiac imaging and long-term heart health with your surgeon when choosing between these procedures.

Endogenous gut-derived GLP-1, secreted in response to nutrients or non-caloric stimuli (like gastrointestinal distension), regulates feeding behavior and glucose metabolism via vagal sensory nerves without causing the adverse effects (nausea/vomiting) associated with GLP-1 receptor agonists.

You can influence your GLP-1 levels naturally. Eating GLP-1-stimulating foods (meat, fish, salad) first, followed by a wait before carbs, improves glycemic control and weight loss. Gastrointestinal distension from bulky, low-energy-density foods also triggers beneficial GLP-1 secretion via vagal nerves without causing nausea.

Weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces liver steatosis and liver enzymes in patients with NAFLD/NASH, but does not significantly improve liver fibrosis or achieve NASH resolution compared to placebo in patients with compensated cirrhosis.

For patients with advanced liver disease (cirrhosis), weekly semaglutide injections (2.4 mg) can significantly reduce liver fat and inflammation markers, but they should not expect it to reverse scarring (fibrosis) or cure NASH. The treatment is safe and effective for metabolic control and steatosis reduction, even if it doesn't change the fibrosis stage.

Resistance training in humans and mechanical overload in rodents does not elevate muscle protein lactylation, challenging the hypothesis that lactate promotes skeletal muscle hypertrophy.

You do not need to maximize lactate accumulation (the 'burn') to trigger muscle protein lactylation or hypertrophy. Resistance training increases blood lactate significantly, but this does not translate to increased muscle protein lactylation or drive hypertrophy via this specific mechanism. Focus on mechanical overload rather than chasing lactate as a signaling molecule for growth.

Pharmacological treatment of prediabetes with anti-hyperglycemic drugs (e.g., metformin, TZDs, insulin) fails to provide long-term protection against diabetes because it does not correct underlying insulin resistance or beta-cell dysfunction, and benefits disappear upon discontinuation.

Standard diabetes drugs (like metformin) do not cure prediabetes. They mask high blood sugar while you take them, but once you stop, your risk of developing diabetes is the same as if you never took the drug. Focus on fixing the root cause (insulin resistance) rather than just lowering the number.

Preoperative use of GLP-1 receptor agonists does not improve long-term weight loss, diabetes remission, or surgical safety outcomes in patients undergoing metabolic bariatric surgery compared to those who do not use GLP-1s.

If you are considering bariatric surgery, using GLP-1 drugs (like Ozempic or Wegovy) beforehand does not appear to make your surgery more successful or your weight loss better in the long run. In fact, it may just delay getting the more effective surgical treatment. If you are experiencing side effects from these drugs or they aren't working well enough, switching to surgery is a valid and effective path, but don't expect the drugs to give you a 'head start' on your results.

Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduces hospital admissions for heart failure and end-stage kidney disease, and decreases mortality in Type 2 Diabetes patients with Chronic Kidney Disease (CKD).

If you have Type 2 Diabetes and Chronic Kidney Disease, ask about Finerenone. It is a non-steroidal medication that helps protect your heart and kidneys, reducing the risk of hospitalization for heart failure and kidney failure, though it requires monitoring for potassium levels.

Sustained administration of PYY(3-36) protects against high-fat diet-induced pancreatic and intestinal morphological deterioration by restoring ileal GLP-1 content and reducing beta-cell turnover.

This research suggests that maintaining healthy gut hormone levels, specifically GLP-1, is crucial for protecting pancreatic health during high-fat diets. While this study used direct PYY(3-36) injection, it supports the broader concept that enhancing incretin activity (like GLP-1) can protect pancreatic structure and function. For individuals, this underscores the importance of dietary patterns that support natural GLP-1 secretion and the potential therapeutic value of incretin-based interventions for metabolic health.

GLP-1 receptor agonists (GLP-1 RAs) are primarily prescribed as anti-diabetic medications (ADMs) rather than anti-obesity medications (AOMs), with 71.8% of first-time prescriptions designated for diabetes management and only 28.2% for obesity.

While GLP-1 medications like semaglutide and tirzepatide are famous for weight loss, the vast majority of prescriptions (over 70%) are for treating Type 2 Diabetes. If you are seeking these medications for weight loss, you may face higher costs and insurance hurdles because they are not primarily covered for obesity in many cases.

Downregulation of the transcription factor NR4A3 in human skeletal muscle, mimicking physical inactivity, impairs glucose oxidation and protein synthesis while increasing fatty acid oxidation and lactate production, leading to muscle atrophy.

Physical inactivity actively suppresses a key protein (NR4A3) in your muscles, which shifts your metabolism away from burning glucose and toward making lactate, while simultaneously shutting down muscle building signals. This molecular change is a primary driver of muscle loss during sedentary periods. While this study was done on cells, it suggests that maintaining NR4A3 levels (e.g., through movement) is crucial for preserving muscle mass and metabolic health, and future therapies might target this pathway.

Dual GLP1R/GIPR agonists achieve superior glucose lowering and weight reduction compared to single GLP1R agonists through specific engagement of pancreatic islet cells (beta, alpha, delta) and circumventricular organ neurons, rather than through enhanced brain penetration.

Dual GLP1/GIP agonists work better than single GLP1 drugs because they target specific cells in the pancreas (beta, alpha, delta) and specific neurons in the brain's edge (circumventricular organs), not because they penetrate the brain deeper. This targeted engagement drives superior glucose and weight outcomes.

Dual GLP1R/GIPR agonists label pancreatic beta, alpha, and delta cells with varying intensity (beta > alpha = delta), engaging distinct receptor nanodomains that differ from those targeted by single agonists.

Dual agonists affect multiple hormone-secreting cells in the pancreas, with the strongest effect on insulin-secreting beta cells, followed by glucagon-secreting alpha and somatostatin-secreting delta cells.

A specific missense variant in the GIP receptor (GIPR, rs1800437, p.Glu354Gln) is associated with an increased risk of vomiting in patients treated with tirzepatide, but not semaglutide.

If you are taking tirzepatide (Mounjaro/Zepbound), your genetics can influence your risk of vomiting. A specific variant in the GIP receptor (rs1800437) is linked to a higher risk of vomiting. This is specific to tirzepatide because it targets both GLP-1 and GIP receptors. If you experience severe vomiting, discussing your genetic history or considering alternative therapies might be beneficial, as this genetic factor does not affect semaglutide users.

Recent safety data from the SELECT trial indicates a higher incidence of hip and pelvic fractures in female patients and those aged 75+ taking semaglutide 2.4 mg weekly compared to placebo.

If you are over 75 or a postmenopausal woman taking semaglutide for heart health, be aware that your risk of hip or pelvic fractures may be slightly higher than if you were not taking the drug. This risk is likely linked to the weight and muscle loss. Ensure you are doing strength training, getting enough calcium/Vitamin D, and discussing bone density scans (DEXA) with your doctor.

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, produces significant weight loss in patients with specific genetic obesity disorders (POMC, LEPR, or PCSK1 deficiency).

Setmelanotide is an FDA-approved treatment for obesity caused by specific genetic mutations (POMC, LEPR, or PCSK1 deficiency). In clinical trials, it led to significant weight loss (up to 51 kg over 42 weeks) in patients with these conditions. It is not for general obesity but targets the underlying hormonal pathway affected by these genetic disorders.

Pharmacologic activation of GIP and GLP-1 receptors rapidly inhibits AgRP neurons, and this neural inhibition contributes to the appetite-suppressing effects of incretin-based obesity therapies.

Incretin-based medications (like semaglutide and tirzepatide) work in part by shutting down hunger-promoting brain cells (AgRP neurons). This mechanism is driven by both GIP and GLP-1 pathways, with dual-action drugs being more effective than single-action ones. This neural inhibition helps explain why these drugs successfully reduce food intake, even in individuals with obesity.

Genetically modeled dual GIPR/GLP1R agonism reduces binge drinking frequency and the risk of heavy drinking with psychiatric comorbidities.

Genetic evidence suggests that activating GLP-1 and GIP receptors (via drugs like semaglutide or tirzepatide) can reduce binge drinking and heavy drinking, especially in those with psychiatric comorbidities. This effect appears independent of general alcohol consumption (drinks per week), suggesting a specific impact on high-risk drinking patterns.

Higher adiposity (BMI) is positively associated with increased striatal dopamine tone in humans, as indicated by the differential displacement of low-affinity D2 receptor tracers.

This research suggests that higher body weight is associated with higher baseline (tonic) dopamine levels in the brain's reward centers. This may alter how rewarding food feels, potentially contributing to overeating. While this doesn't provide a direct 'fix,' it highlights that obesity is a neurochemical state, not just a willpower failure. Interventions might need to account for this altered reward sensitivity.